Spiro Ring System Containing Patents (Class 514/252.15)
-
Publication number: 20100144714Abstract: The present invention relates to new derivatives of imidazo, pyrimido and diazepine-pyrimidine-dione of the general formula (I) in which R1, R2, L1, L2, Y, Z and A are various and varying groups. These products exhibit a good affinity for certain sub-types of cannabinoid receptors, in particular the CB2 receptors. They are particularly useful for treating pathological conditions and diseases in which one or more cannabinoid receptors are involved. The invention also relates to pharmaceutical compositions containing said products, and to the use thereof for preparing a drug.Type: ApplicationFiled: December 17, 2007Publication date: June 10, 2010Applicant: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.)Inventors: Lydie Poitout, Valérie Brault
-
Publication number: 20100130501Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formulas A and B: (A) and (B) wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications, cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disase pression, virus diseases, inflammatory disorders, or diseases in which the liver is a target organ.Type: ApplicationFiled: February 4, 2008Publication date: May 27, 2010Inventors: Hui Li, Seiji Nukui, Stephanie Anne Scales, Min Teng, Chunfeng Yin
-
Publication number: 20100130506Abstract: A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.Type: ApplicationFiled: December 10, 2008Publication date: May 27, 2010Inventors: Gurdip BHALAY, Emma Budd, Graham Charles Bloomfield, Stephen Paul Collingwood, Andrew Dunstan, Lee Edwards, Peter Gedeck, Catherine Howsham, Peter Hunt, Thomas Anthony Hunt, Paul Oakley, Nichola Smith
-
Publication number: 20100120719Abstract: This invention relates to a pharmaceutical kit containing a lyophilized preparation of a pyrimidine compound described in the specification. Also disclosed is a lyophilization process for making this preparation.Type: ApplicationFiled: November 12, 2009Publication date: May 13, 2010Applicant: TaiGen Biotechnology Co., Ltd.Inventors: Chi-Feng Yen, Judy Yuan, Chi-Hsin Richard King
-
Patent number: 7704996Abstract: The present invention relates to the use of a 2-cyanopyrimidine compound of the formula wherein R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.Type: GrantFiled: August 16, 2005Date of Patent: April 27, 2010Assignee: Novartis AGInventors: Terance William Hart, Allan Hallett, Fumiaki Yokokawa, Hajime Hirao, Takeru Ehara, Atsuko Iwasaki, Junichi Sakaki, Keiichi Masuya, Masashi Kishida, Osamu Irie
-
Publication number: 20100075950Abstract: The present invention relates to new phenylpropanone modulators of dopamine receptors, serotonin receptors, and/or nicotinic acetylcholine receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: August 19, 2009Publication date: March 25, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Manouchehr M. Shahbaz, Sepehr Sarshar
-
Publication number: 20100056537Abstract: The present invention is directed to the provision of pharmaceutical compositions such as multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy preservative efficacy requirements in the United States and/or Europe. The compositions include sorbate or a non-polymeric diquaternary ammonium compound for enhancing preservation efficacy. Further, the compositions typically have relatively low ionic strengths to assist in maintaining such efficacy.Type: ApplicationFiled: August 28, 2009Publication date: March 4, 2010Inventors: Malay Ghosh, Masood A. Chowhan
-
Publication number: 20100009983Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, in combination with one or more other neurogenic agents, or anti-astrogenic agent, to stimulate or activate the formation of new nerve cells.Type: ApplicationFiled: June 25, 2009Publication date: January 14, 2010Applicant: BrainCells, Inc.Inventors: Carrolee Barlow, Todd A. Carter, Andrew Morse, Kai Treuner, Kym I. Lorrain
-
Publication number: 20090047234Abstract: The present invention concerns a method of administering at least one active pharmaceutical agent to a patient in need thereof, which method comprises the intranasal administration of a composition comprising a therapeutically effective amount of this agent, phospholipids, one or more C2-C4 alcohols and water, wherein the concentrations of the phospholipids and the one or more alcohols in the composition are in the ranges of 0.2 to 10% and 12 to 30% by weight, respectively, with the water content of said composition being not less than 30% by weight, the phospholipids forming vesicles in said composition. Further are disclosed pharmaceutical compositions and combinations suitable for intranasal delivery.Type: ApplicationFiled: March 28, 2008Publication date: February 19, 2009Inventors: Elka Touitou, Biana Godin, Shaher Duchi
-
Publication number: 20090042861Abstract: The present invention provides a prophylactic or therapeutic agent for depression or anxiety disorders, comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide.Type: ApplicationFiled: April 3, 2006Publication date: February 12, 2009Applicant: Takeda Pharmaceutical Company LimitedInventors: Keisuke Hirai, Masaomi Miyamoto
-
Patent number: 7482346Abstract: The present invention comprises alkylpiperazine- and alkylhomopiperazine carboxylates and their derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase (FAAH) enzyme inhibitors. These derivatives exert various pharmacological activities by interacting, inter alia, with cannabinoid and vanilloid receptors. By inhibiting the metabolic activity of the FAAH enzyme, compounds often responsible for the onset of disease and other pathological conditions are not generated and the incidence of the disease is greatly reduced.Type: GrantFiled: August 22, 2006Date of Patent: January 27, 2009Assignee: Sanofi-AventisInventors: Ahmed Abouabdellah, Antonio Almario Garcia, Christian Hoornaert, Tak Adrien Li
-
Publication number: 20090023744Abstract: A combination therapy for treating depressive disorders is provided herein. The combination therapy comprises administering an effective amount of bupropion or its metabolites together with at least one serotonin 5-HT1A partial agonist or its metabolites to a patient in need of treatment of the depressive disorder. Pharmaceutical formulations, including packaged pharmaceutical formulations, comprising this combination are also provided herein.Type: ApplicationFiled: June 17, 2008Publication date: January 22, 2009Applicant: The General Hospital CorporationInventor: Maurizio Fava
-
Patent number: 7452886Abstract: The invention provides compounds of Formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.Type: GrantFiled: August 29, 2002Date of Patent: November 18, 2008Assignee: Novartis AGInventors: Claudia Betschart, Kenji Hayakawa, Osamu Irie, Junichi Sakaki, Genji Iwasaki, Rene Lattmann, Martin Missbach, Naoki Teno
-
Patent number: 7238693Abstract: The present invention relates to novel compounds, the preparation and use, particularly therapeutic, thereof. More specifically, it relates to compounds derived from aryl carbamates, the preparation and use thereof, particularly in the field of human and animal health. The compounds according to the invention are preferably 5-HT4 serotoninergic receptor ligands and can therefore be used in the therapeutic or prophylactic treatment of any disorder involving a 5-HT4 receptor. The invention also relates to pharmaceutical compositions comprising such compounds, the preparation and use thereof and treatment methods using said compounds.Type: GrantFiled: February 22, 2002Date of Patent: July 3, 2007Assignees: Cerep, Centre National de la Recherche Scientifique, Institut National de la Santa et de la Recherche Medicale (inserm)Inventors: Eric Nicolai, Sophie Curtet, James Sicsic, Frank Lezoualc'h, Rodolphe Fischmeister, Michel Langlois, Magali Maillet, Michèle Launay
-
Patent number: 7214676Abstract: The invention provides compounds which are PDE7 inhibitors, having the following formula (I), (II) and (III) in which X1, X2, X3, X4, X, Y, Z, A and Z1 are as defined in the description, methods for preparing them and their use for the treatment of disorders for which therapy by a PDE7 inhibitor is relevant.Type: GrantFiled: May 24, 2004Date of Patent: May 8, 2007Assignee: Warner-Lambert Company LLCInventors: Patrick Bernardelli, Pierre Ducrot, Edwige Lorthiois, Febrice Vergne
-
Patent number: 7091343Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.Type: GrantFiled: March 14, 2003Date of Patent: August 15, 2006Assignee: Vertex Pharmaceuticals IncorporatedInventors: David Bebbington, Hayley Binch, Jean-Damien Charrier, Simon Everitt, Julian M. C. Golec, David Kay, Ronald Knegtel, Andrew Miller, Francoise Pierard
-
Patent number: 7071194Abstract: The present invention provides a method for improving respiratory function and inhibiting muscular degeneration (e.g., dystrophy and atrophy). Alternative embodiments of the invention provide a method of inhibiting motor neuron apoptosis and the subsequent muscular degeneration associated with the denervation of muscular tissue resulting from neuron death.Type: GrantFiled: September 13, 2002Date of Patent: July 4, 2006Assignee: The Children's Medical Center CorporationInventor: Yang D. Teng
-
Patent number: 6821976Abstract: The S-stereoisomer of 6-hydroxy-buspirone is an effective treatment for anxiety, depression, and other psychogenic disorders. The S-isomer may provide reduced potential for adverse effects and a longer duration of action compared to the racemic mixture and with buspirone.Type: GrantFiled: July 22, 2002Date of Patent: November 23, 2004Assignee: Bristol-Myers Squibb CompanyInventors: Joseph P. Yevich, Robert F. Mayol, Jianqing Li, Frank Yocca
-
Patent number: 6803368Abstract: Compounds of the formula useful for treatment of disorders of the dopaminergic system, such as schizophrenia, schizoaffective disorder, bipolar disorder, Parkinson's disease, L-DOPA induced pychoses and dyskinesias, Tourette's syndrome and hyperprolactinemia and in the treatment of drug addiction such as the addiction to ethanol, nicotine or cocaine and related illnesses.Type: GrantFiled: April 23, 2002Date of Patent: October 12, 2004Assignee: WyethInventors: Gary P. Stack, James A. Nelson
-
Publication number: 20040151670Abstract: A liquid aerosol formulation comprising at least one thermally stable active ingredient selected from the group consisting of buspirone, buprenorphine, triazolam, cyclobenzaprine, zolpidem, pharmaceutically acceptable salts and esters thereof and derivatives thereof. The liquid formulation can include an organic solvent such as propylene glycol and one or more optional excipients. The active ingredient can be present in an amount of 0.01 to 5 wt. % and the formulation can be heated to provide a vapor which forms an aerosol having a mass median aerodynamic diameter of less than 3 &mgr;m.Type: ApplicationFiled: December 15, 2003Publication date: August 5, 2004Inventors: Frank E. Blondino, Justin Poklis, Matthew Baker
-
Publication number: 20040106623Abstract: This invention is directed towards a method of inhibiting activation of a human &agr;1d adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor, wherein the compound binds selectively to a human &agr;1d adrenergic receptor. This invention provides for a compound which binds selectively to a human &agr;1d adrenergic receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier. This invention further provides for a method of treating a subject afflicted with a disease which is susceptible to treatment by antagonism of the human &agr;1d adrenergic receptor which comprises administering to the subject an amount of the above defined compounds effective to treat the disease.Type: ApplicationFiled: November 20, 2003Publication date: June 3, 2004Applicant: Synaptic Pharmaceutical CorporationInventors: Michael Konkel, John M. Wetzel, Stewart A. Noble, Charles Gluchowski, Douglas A. Craig
-
Patent number: 6743798Abstract: The present invention relates to novel substituted pyrazole derivatives of the general formula (I) in which R1, R2, R3 and A are each as defined, and to processes for their preparation and to their use as medicaments, in particular as medicaments for the treatment of cardiovascular disorders.Type: GrantFiled: April 11, 2001Date of Patent: June 1, 2004Assignee: Bayer AktiengesellschaftInventors: Alexander Straub, Achim Feurer, Cristina Alonso-Alija, Johannes-Peter Stasch, Elisabeth Perzborn, Joachim Hütter, Klaus Dembowsky, Elke Stahl
-
Publication number: 20040067956Abstract: The invention relates to the use of compounds that enhance 5-hydroxytryptamine 1a receptor activity, or activation (e.g. a selective 5-hydroxytryptamine 1a receptor agonists) for preventing or reducing motor fluctuations associated with dopamine replacement therapy.Type: ApplicationFiled: June 27, 2003Publication date: April 8, 2004Inventors: Jonathan Brotchie, Michael Hill
-
Publication number: 20040023948Abstract: This invention relates to a pharmaceutical composition for oral administration comprising a carrier and, as an active ingredient, a 5-HT1 agonist, characterized in that the composition is formulated to reduce pre-systemic metabolism of said 5-HT1 agonist. A process for preparing such a composition and the use of such a composition for the treatment of anxiety, depression, attention deficit disorder and/or panic disorders and/or as a memory enhancer are also provided.Type: ApplicationFiled: February 26, 2003Publication date: February 5, 2004Inventors: Richard David Green, Jonathan Lacy, Nicholas Mallard, Edward Johnson
-
Patent number: 6686361Abstract: The R-stereoisomer of 6-hydroxy-buspirone is an effective treatment for anxiety, depression, and other psychogenic disorders. The R-isomer exhibits greater receptor specificity than the S-isomer and should have reduced potential for the adverse effects associated with the racemic mixture and with buspirone.Type: GrantFiled: July 22, 2002Date of Patent: February 3, 2004Assignee: Bristol-Myers Squibb CompanyInventors: Joseph P. Yevich, Robert F. Mayol, Jianqing Li, Frank Yocca
-
Publication number: 20040002500Abstract: The present invention relates to a method for treatment of attention deficit disorder by administering certain 5-HT1A receptor agonistsType: ApplicationFiled: June 28, 2002Publication date: January 1, 2004Applicant: Fabre Kramer Pharmaceutical, Inc.Inventors: Stephen J. Kramer, Louis F. Fabre
-
Patent number: 6649614Abstract: The present invention relates to the treatment of depression and/or anxiety by the administration of a combination of a specific class of NK-1 receptor antagonists and an antidepressant or anti-anxiety agent.Type: GrantFiled: October 16, 2001Date of Patent: November 18, 2003Assignee: Merck Sharp & Dohme Ltd.Inventors: Emma Joanne Carlson, Nadia Melanie Rupniak
-
Publication number: 20030207890Abstract: Compositions and methods for treating disorders of the outer retina with compounds with 5-HT1A against activity are disclosed.Type: ApplicationFiled: September 9, 2002Publication date: November 6, 2003Inventors: Robert J Collier, Michael A Kapin, Mark R Hellberg, Thomas R Dean
-
Patent number: 6617329Abstract: Compounds of the formula having an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and air-ways, and the preparation thereof.Type: GrantFiled: August 23, 2001Date of Patent: September 9, 2003Assignee: Boehringer Ingelheim Pharma KGInventors: Frank Himmelsbach, Elke Langkopf, Birgit Jung, Stefan Blech, Flavio Solca
-
Publication number: 20030139395Abstract: This invention relates to a method of treating depression and anxiety-related disorders comprising administering to a mammal in need of such treatment an effective amount of a combination of an adenosine A2A antagonist and an antidepressant or an anxiolytic; another aspect of the invention is a pharmaceutical composition comprising a therapeutically effective amount of a combination of an adenosine A2A antagonist and an antidepressant or anxiolytic in a pharmaceutically acceptable carrier.Type: ApplicationFiled: September 11, 2002Publication date: July 24, 2003Applicant: Schering CorporationInventors: William Greenlee, John Hunter
-
Publication number: 20030139422Abstract: The present invention provides a method for improving respiratory function and inhibiting muscular degeneration (e.g., dystrophy and atrophy). Alternative embodiments of the invention provide a method of inhibiting motor neuron apoptosis and the subsequent muscular degeneration associated with the denervation of muscular tissue resulting from neuron death.Type: ApplicationFiled: September 13, 2002Publication date: July 24, 2003Applicant: The Children's Medical Center CorporationInventor: Yang D. Teng
-
Publication number: 20030119846Abstract: Compounds with 5-HT1A agonist activity which are useful for controlling the visual field loss associated with glaucoma are disclosed.Type: ApplicationFiled: September 9, 2002Publication date: June 26, 2003Inventors: Robert J. Collier Jr, Mark R. Hellberg, Thomas R. Dean
-
Patent number: 6579899Abstract: A method of treating stress in a patient showing stress related symptoms is disclosed, where the method comprises administering to the patient an effective amount of a serotoninergic drug or prodrug. Specific examples of such drugs are described, and include, among others, tryptophan or 5-hydroxytryptophan, or their salts.Type: GrantFiled: January 27, 2000Date of Patent: June 17, 2003Assignee: Massachusetts Institute of TechnologyInventors: Judith J. Wurtman, Richard J. Wurtman
-
Patent number: 6566361Abstract: A method of treating pain with acetaminophen comprises the concurrent administration of an azapirone such as buspirone. This combination of agents surprisingly results in a strengthened analgesic response characterized by rapid onset, greater pain relief, and a longer duration of action.Type: GrantFiled: May 17, 2001Date of Patent: May 20, 2003Assignees: Laboratories, UPSA, Bristol-Myers Squibb CompanyInventors: Francoise Camborde, Alix Cloarec, Charles Conway
-
Publication number: 20030069251Abstract: An improved method of treating anxious patients involves direct administration of 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-piperazinyl]-butyl]-8-azaspiro[4.5]-7,9-dione (BMY 28674) or a pharmaceutically acceptable salt or hydrate formulated in appropriate pharmaceutical compositions to patients in need of such treatment. Syntheses of BMY 28674 are also provided.Type: ApplicationFiled: July 23, 2002Publication date: April 10, 2003Inventors: Joseph P. Yevich, Robert F. Mayol, Jianqing Li, Edward H. Ruediger
-
Patent number: 6541478Abstract: Nicotine dependency is treated by administration of an opioid antagonist. In some embodiments, rapid or ultra rapid detoxification techniques include using a combination of an effective amount of an opioid antagonist such as nalmefene, naloxone or naltrexone or a mixture of any one of these, and either clonidine or related compounds either while awake, or while under sedation or anesthesia, followed by continued administration of an effective amount of an opioid antagonist with or without agents that enhance nicotine dependency treatment.Type: GrantFiled: September 16, 1999Date of Patent: April 1, 2003Assignee: Yale UniversityInventors: Stephanie O'Malley, Boris Meandzija, Suchitra Krishnan-Sarin
-
Publication number: 20030022899Abstract: The S-stereoisomer of 6-hydroxy-buspirone is an effective treatment for anxiety, depression, and other psychogenic disorders. The S-isomer may provide reduced potential for adverse effects and a longer duration of action compared to the racemic mixture and with buspirone.Type: ApplicationFiled: July 22, 2002Publication date: January 30, 2003Inventors: Joseph P. Yevich, Robert F. Mayol, Jianqing Li, Frank Yocca
-
Patent number: 6511982Abstract: A method of treating pain with acetaminophen comprises the concurrent administration of buspirone. This combination of agents surprisingly results in a morphine-like analgesic response characterized by rapid onset, greater pain relief, and a longer duration of action.Type: GrantFiled: January 4, 2001Date of Patent: January 28, 2003Assignee: Bristol-Myers Squibb CompanyInventors: Francoise Camborde, Alix Cloarec, Charles Conway
-
Publication number: 20020193380Abstract: A method of treating pain with acetaminophen comprises the concurrent administration of a hydroxyazapirone selected from 6-hydroxybuspirone or 3-hydroxygepirone. This combination of agents results in a more morphine-like analgesic response characterized by rapid onset and greater pain relief.Type: ApplicationFiled: April 4, 2002Publication date: December 19, 2002Inventors: Francoise Camborde, Alix Cloarec, Charles Conway
-
Publication number: 20020147201Abstract: The products and methods of the present invention provide a means for increasing the solubility and bioavailability of active agents. More particularly the invention provides compositions containing active agents as water-soluble complexes with glycyrrhizin, and methods of preparing such complexes. The invention further provides methods for the preparation of highly water soluble complex dosage forms.Type: ApplicationFiled: February 8, 2002Publication date: October 10, 2002Applicant: Lavipharm Laboratories Inc.Inventors: Li-Lan H. Chen, Li Tao, Alfred Liang
-
Compounds having heterocyclic groups containing two nitrogen atoms for treating multidrug resistance
Publication number: 20020115659Abstract: Compounds having heterocyclic groups containing two nitrogen atoms are disclosed. The compounds are useful for treating multidrug resistance. The compounds can be formulated in compositions with a carrier and, optionally, a therapeutic agent.Type: ApplicationFiled: December 19, 2000Publication date: August 22, 2002Inventors: Charles Raymond Degenhardt, David Joseph Eickhoff -
Publication number: 20020091120Abstract: Compounds, compositions, and methods for treating multidrug resistance are disclosed. Suitable compounds are 2-substituted heterocyclic compounds.Type: ApplicationFiled: December 19, 2000Publication date: July 11, 2002Inventors: Charles Raymond Degenhardt, David Joseph Eickhoff
-
Publication number: 20020032215Abstract: A method of treating pain with acetaminophen comprises the concurrent administration of an azapirone such as buspirone. This combination of agents surprisingly results in a strengthened analgesic response characterized by rapid onset, greater pain relief, and a longer duration of action.Type: ApplicationFiled: May 17, 2001Publication date: March 14, 2002Inventors: Francois Camborde, Alix Cloarec, Charles Conway
-
Publication number: 20010025038Abstract: A method of reducing cravings in a mammal to food or an addictive substance is disclosed. The method comprises administering to the mammal an effective amount of a D1/D5 antagonist or a D1/D5 partial agonist alone or in combination with other specified CNS compounds.Type: ApplicationFiled: May 1, 2001Publication date: September 27, 2001Inventors: Vicki L. Coffin, Paul W. Glue
-
Publication number: 20010016584Abstract: A method of treating pain with acetaminophen comprises the concurrent administration of buspirone. This combination of agents surprisingly results in a morphine-like analgesic response characterized by rapid onset, greater pain relief, and a longer duration of action.Type: ApplicationFiled: January 4, 2001Publication date: August 23, 2001Inventors: Francoise Camborde, Alix Cloarec, Charles Conway
-
Publication number: 20010014678Abstract: The present invention encompasses methods of treating patients for tobacco addiction and nicotine addiction, for palliating the effects of nicotine withdrawal, for providing or facilitating the effects of smoking cessation therapies and as long-term smoking cessation maintenance therapy. The invention also includes related pharmaceutical compositions comprising nicotine receptor antagonists and either an anti-depressant or an anti-anxiety drug. Specific combinations of drugs (mecamylamine HCl and bupropion HCl) as well as mecamylamine in combination with certain drug classes (e.g., anti-anxiety drugs and anti-depressants) comprise the pharmaceutical compositions disclosed. These compositions are also contemplated for use in the treatment of cocaine addiction and the treatment of alcohol dependence.Type: ApplicationFiled: February 20, 2001Publication date: August 16, 2001Applicant: CARY MEDICAL CORPORATIONInventor: Douglas D. Cary
-
Patent number: 6268368Abstract: A controlled release form of buspirone medicament is described. This medicament comprises a buspirone in intimate admixture with an anionic exchange polymer complexing agent. These components form a complex upon the addition of water and thereby permit improved dosing of buspirone to achieve a more targeted therapeutic effect in patients.Type: GrantFiled: March 1, 2000Date of Patent: July 31, 2001Assignee: American Pharmaceuticals InternationalInventors: Arthur H. Goldberg, Ahmed Adel Sakr
-
Publication number: 20010009913Abstract: An improved method of orally dosing buspirone in a manner favoring production of the active metabolite 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-piperazinyl]-butyl]-8-azaspiro[.5]-7,9-dione should enhance the alleviation of anxiety in anxious patients.Type: ApplicationFiled: March 8, 2001Publication date: July 26, 2001Inventor: Robert F. Mayol
-
Patent number: 6218395Abstract: A combination of medicines are administered daily for the relief of the symptoms of an Anxiety Disorder or an Adjustment Disorder With Anxiety. The combination comprises a centrally-acting beta-blocker which passes the brain blood barrier, preferably the beta-blocker betaxolol, and a serotonin-enhancer, for example, the serotonin agonist buspirone or the serotonin reuptake inhibitor sertraline.Type: GrantFiled: August 2, 1999Date of Patent: April 17, 2001Inventor: Conrad Melton Swartz